Compare IRDM & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRDM | LQDA |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 2007 | 2020 |
| Metric | IRDM | LQDA |
|---|---|---|
| Price | $45.81 | $58.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $48.00 | ★ $63.88 |
| AVG Volume (30 Days) | 800.0K | ★ 3.1M |
| Earning Date | 10-20-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | 12.77 | ★ 51.81 |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $871,659,000.00 | $158,320,000.00 |
| Revenue This Year | $6.53 | $379.72 |
| Revenue Next Year | $7.90 | $17.90 |
| P/E Ratio | $36.17 | ★ N/A |
| Revenue Growth | 4.93 | ★ 1031.18 |
| 52 Week Low | $15.65 | $22.31 |
| 52 Week High | $57.18 | $93.61 |
| Indicator | IRDM | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.64 | 68.22 |
| Support Level | $43.68 | $53.06 |
| Resistance Level | $46.54 | $63.46 |
| Average True Range (ATR) | 1.44 | 3.36 |
| MACD | 0.35 | 2.38 |
| Stochastic Oscillator | 73.29 | 97.85 |
Iridium Communications Inc is the commercial provider of communications services offering true globalised coverage, connecting people, organizations, and assets to and from anywhere, in real time. The company is a provider of mobile voice and data communications services through a constellation of low-earth-orbiting satellites. Iridium's solutions are ideally suited for industries such as maritime, aviation, government/military, emergency/humanitarian services, mining, forestry, oil and gas, heavy equipment, transportation, and utilities. Iridium also provides service to subscribers from the U.S. Department of Defense, as well as other civil and government agencies world-wide. The Company operates in one business segment, providing satellite communications services and products.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.